Handling data below the limit of quantification in mixed effect models.
about
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria.Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.The present and future of withdrawal period calculations for milk in the European Union: dealing with data below the limit of quantification.Missing data in model-based pharmacometric applications: points to consider.Tips and traps analyzing pediatric PK data.Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models.Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.First-dose pharmacokinetics of lithium carbonate in children and adolescents.Use of pharmacokinetic data below lower limit of quantitation valuesExtension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model.Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder.Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCRPopulation pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria.Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy.Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in UgandaA multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric EpendymomaEarly prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements.Population Pharmacokinetic Modelling of FE 999049, a Recombinant Human Follicle-Stimulating Hormone, in Healthy Women After Single Ascending DosesDevelopment of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjectsPopulation pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibody.Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patientsValidation and Application of a Dried Blood Spot Assay for Biofilm-Active Antibiotics Commonly Used for Treatment of Prosthetic Implant Infections.HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake.Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.Population pharmacokinetic modeling and dosing simulations of nitrogen-scavenging compounds: disposition of glycerol phenylbutyrate and sodium phenylbutyrate in adult and pediatric patients with urea cycle disordersPopulation pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification.Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six-Minute Walk Test.In Vitro and In Vivo Modeling of Hydroxypropyl Methylcellulose (HPMC) Matrix Tablet Erosion Under Fasting and Postprandial Status.Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: a Novel Method to Handle the Interval Censoring Caused by Measurement of Smaller Tumors.Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention.Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection.Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B.
P2860
Q30499990-71DD3B42-E0B6-4F31-9312-93C86332FBF5Q30655795-FF6B734D-2341-47FD-BA52-76DD229A14E9Q30867699-AEEE2250-2DD3-4CAF-BEAE-658BC6E6245AQ30964404-61FD5826-3B2B-437C-89E8-FB5940248BA4Q31118795-3019F6FE-444E-443B-A0BE-05883155BC0CQ33706156-CC983A44-5B67-4C84-B509-568A0C6E8764Q33820152-E88F2E83-D876-4BFD-95FF-9B0CE2DD2C7CQ33917058-A00F610C-9B99-4DBF-8395-87144F9403A3Q34037355-C37C2593-EABC-4EF2-A8D6-C5C1EE6FF118Q34257156-E6E50FE4-834D-47F7-BCD8-4B1DE02D7134Q34315916-6800536C-2616-451A-9F72-550A408A4AF4Q34376951-F6D8DF78-336D-4D49-AAFD-9E8E8D3C4116Q34700914-A0DDD22C-00AC-4DC9-A998-D471ECFEBB48Q34737629-57BBFBC1-7A7D-420D-9CB9-31CC77F4E546Q35363704-A0841E20-4555-4238-B854-6390002B8969Q35746272-DDC21BE5-E34F-4F49-BF29-86432C97E8D4Q35867343-D604ED8A-3C0E-4038-AB51-59B40491609FQ36364248-38A2D54A-FB33-4738-97E7-0C0B2A414CDFQ36411652-DF453363-7F4D-40E0-AAB1-5C4CE3A6E7FBQ36684146-98707CBD-BF27-4E33-886F-50C66302A597Q36729959-2C4EF9D1-73E9-40D9-BDF9-527E49F13EE7Q36805228-BAC8A46F-2FCC-4058-8FED-C30CFC7C0599Q36876448-85A40155-AEB4-4B1F-9A3D-4D063E8C13C9Q36924006-74754A0D-D388-465C-9D49-A4E0FE44A39FQ36969875-AF449AD6-6D11-42F5-9606-E97680666619Q37030693-36E93B27-737E-4C88-8AAD-56142971D49CQ37030730-4AE64262-5942-4802-B573-1E73B9D7672BQ37120112-92BCC92D-CF3A-40AB-A486-F4B3160B8032Q37287701-7E21B83E-3E09-46E5-B56D-A6DF2F0FDBADQ37540015-B2DE92D7-3DE8-4FAD-840A-10B884597D5AQ37544479-B3FF0CE3-5098-44C2-B6D2-5AF6C607B1AAQ37582146-ABE0FBAE-B34A-4C18-99FC-3148FEB8F122Q38666988-F95950A2-EB30-40CC-A9FA-8FF9B238C7C2Q38703261-0BAAFBF2-9A78-445F-9DBD-F155DF231B3FQ38712657-0BF24FE1-BC4D-4398-938C-3B2F10B0C070Q38762373-1FFE4D73-0B9C-44B9-A2C5-27F8A4606610Q38790656-737FDB7B-4BFD-424C-97AA-62134C3242EEQ38905356-63ABD3A6-02CD-46DE-8AF2-9F298F2D0B6EQ38905403-117CC634-8BAD-4728-A638-76197374D1EBQ38935228-D019B479-D7EB-4C6F-87D0-21921F718110
P2860
Handling data below the limit of quantification in mixed effect models.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Handling data below the limit of quantification in mixed effect models.
@ast
Handling data below the limit of quantification in mixed effect models.
@en
type
label
Handling data below the limit of quantification in mixed effect models.
@ast
Handling data below the limit of quantification in mixed effect models.
@en
prefLabel
Handling data below the limit of quantification in mixed effect models.
@ast
Handling data below the limit of quantification in mixed effect models.
@en
P2860
P1433
P1476
Handling data below the limit of quantification in mixed effect models.
@en
P2093
Mats O Karlsson
P2860
P2888
P304
P356
10.1208/S12248-009-9112-5
P407
P577
2009-05-19T00:00:00Z
P5875
P6179
1052140882